Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: A randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie

Published 2015 View Full Article

Authors

Keywords

Gastric cancer, HER2, EGFR, Lapatinib

Journal

EUROPEAN JOURNAL OF CANCER

Volume 51, Issue 5, Pages 569-576

Publisher

Elsevier BV

Online

2015-02-16

DOI

10.1016/j.ejca.2015.01.059

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Publish scientific posters with Peeref

Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.

Learn More

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started